Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOCIRET Trial
2017-001429-41Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in Idiopathic retroperitoneal fibrosis (RPF), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoint: Remission rate at month 6. Started Oct 2021; status: terminated.
02
Drugs
tocilizumab
03
Conditions
Idiopathic retroperitoneal fibrosis (RPF)
Beyond the preview
Go deeper on 2017-001429-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001429-41.